Deep Science Ventures (DSV), a UK-based deeptech venture creator, and Medicines Discovery Catapult (MDC), a life sciences service dedicated to turning drug discovery into commercial breakthroughs, today announced a strategic collaboration to address challenges in delivering medicines into the brain.
While recent scientific breakthroughs have identified numerous targets for neurological conditions, the difficulty of effectively transporting these treatments across the blood-brain barrier and into the central nervous system (CNS) remains a primary challenge for global health.
According to the World Health Organization’s Global Status Report on Neurology, over 40 per cent of the global population is living with CNS diseases, making them a leading global cause of ill health and disability.
Developing new solutions could unlock access for rare neurological disorders and expand treatment to large or underserved patient populations, including those with diseases like Alzheimer’s and Parkinson’s and various brain cancers.
Directly addressing critical gaps in healthcare means these innovations have the potential to improve patient outcomes while creating clinical and commercial opportunities for biotech and pharma companies. The first phase of the partnership will see an in-depth review of the current medicines landscape conducted to identify opportunities for innovation.
